merged_eli-lilly-zepbound-price.txt

<question_number>1</question_number>
<answer>positioning its vials as a safer option than compounded drugs which have less oversightanswer>
<question_number>2</question_number>
<answer>offering its own telehealth platform that connects patients with providers and allows direct purchase from Lilly</answer>
<question_number>3</question_number>
<answer>compounded drugs are not FDA-approved and not controlled for safety, quality, and effectiveness</answer>
<question_number>4</question_number>
<answer>offering lower-priced alternative to regain customers currently getting compounded tirzepatide</answer>
<question_number>5</question_number>
<answer>compounding pharmacies can only legally produce alternative versions of medications on FDA's shortage list</answer>
<question_number>6</question_number>
<answer>offering transparent pricing by removing third-party supply chain entities</answer>
<question_number>7</question_number>
<answer>health risks for older patients including loss of muscle mass, increased likelihood of fractures or frailty</answer>
<question_number>8</question_number>
<answer>making patients perceive compounded drugs as less safe compared to FDA-approved vials</answer>
<question_number>9</question_number>
<answer>being listed by the FDA as "in shortage"</answer>
<question_number>10</question_number>
<answer>offering lower pricing as a signal to compete with compounding pharmacies</answer>